83 Covid cases of Delta plus variant reported in India till Aug 4: Govt

New Delhi: A total of 83 cases of Delta plus variant of COVID-19 have been reported in India till August 4 with Maharashtra registering 33 of these cases followed by Madhya Pradesh with 11 and Tamil Nadu 10, the Lok Sabha was informed on Friday. Responding to a question on whether private laboratories are permitted to do genome sequencing of coronavirus, Minister of State for Health Bharati Pravin Pawar in a written reply said inclusion of private labs in Indian INSACOG (SARS-CoV-2 Genomic Consortium) is under consideration.

“Few labs have submitted their willingness to be part of INSACOG. Their inclusion will be decided based on capacity assessment with respect to their human resources and infrastructure,” she said in her reply.

Analysis of the genomic data is a continuous and ongoing process. Periodic updates are shared with experts and states and are also regularly made available in the public domain through the media bulletin of INSACOG.

States are regularly advised to send samples for genome sequencing and provide clinical data of positive persons to enable greater epidemiological insights to identify link between surge in cases at various places to the variants, the minister stated.

Elaborating on the steps being taken to check the spread of the Delta variant, Pawar said to monitor the variants of SARS-CoV-2 virus, initially genomic sequencing was conducted through National Institute of Virology, Pune.

Subsequently, the Centre established Indian SARS-CoV-2 Genomic Consortium (INSACOG) in December 2020 as a consortium of 10 laboratories of Ministry of Health, Department of Biotechnology, Indian Council of Medical Research (ICMR) and Council of Scientific and Industrial Research (CSIR).

The network of INSACOG laboratories has since been increased to 28, Pawar stated.

While monitoring the prevalence of variants through the network of labs, according to advice from experts it is noted that the public health measures to manage the pandemic in the field and the treatment protocol remain the same and the five-fold strategy of test-track-treat-vaccinate and Covid-appropriate behavior is to be followed at the field level, she said. PTI PLB ZMN ZMN

  • Related Posts

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    New Delhi: Aurobindo Pharma Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic version of glycerol phenylbutyrate oral liquid…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India